Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Climb Bio, Inc. - Common Stock (NQ:CLYM)

1.950 +0.010 (+0.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,415,968
Open 2.060
Bid (Size) 1.910 (6)
Ask (Size) 2.040 (11)
Prev. Close 1.940
Today's Range 1.910 - 2.300
52wk Range 1.050 - 5.270
Shares Outstanding 26,993,401
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga

Performance

YTD
-5.8%
-5.8%
1 Month
-3.0%
-3.0%
3 Month
+33.6%
+33.6%
6 Month
+54.8%
+54.8%
1 Year
-61.1%
-61.1%

More News

Read More
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
From Climb Bio, Inc.
Via GlobeNewswire
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Which stocks are moving after the closing bell on Friday?
Via Chartmill
Top movers in Thursday's after hours session
Via Chartmill
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Friday's after hours session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Climb Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to be Added to the Nasdaq Biotechnology Index
From Climb Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Climb Bio, Inc. - Common Stock publicly traded?
Yes, Climb Bio, Inc. - Common Stock is publicly traded.
What exchange does Climb Bio, Inc. - Common Stock trade on?
Climb Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Climb Bio, Inc. - Common Stock?
The ticker symbol for Climb Bio, Inc. - Common Stock is CLYM on the Nasdaq Stock Market
What is the current price of Climb Bio, Inc. - Common Stock?
The current price of Climb Bio, Inc. - Common Stock is 1.950
When was Climb Bio, Inc. - Common Stock last traded?
The last trade of Climb Bio, Inc. - Common Stock was at 10/16/25 04:00 PM ET
What is the market capitalization of Climb Bio, Inc. - Common Stock?
The market capitalization of Climb Bio, Inc. - Common Stock is 52.64M
How many shares of Climb Bio, Inc. - Common Stock are outstanding?
Climb Bio, Inc. - Common Stock has 53M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.